Innovators and Service Providers

Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is advancing to Phase 2 clinical trials.

Berkeley FIT is a company that fosters innovation through technology by partnering with renowned companies and startups. They are creators, engineers, designers, and thinkers who integrate cutting-edge technologies to empower their partners to innovate, adapt, and thrive in an ever-evolving digital landscape.

Celestial Therapeutics is a Johnson & Johnson Innovations - JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.

Cohesys is a clinical-stage company focused on innovating fracture repair solutions. Its product, BoneTape, is the first bone fixation device that does not require drilling into healthy bone. The company aims to disrupt the traditional surgical-repair industry that relies on invasive plates and screws.

CranioSense, Inc. is a clinical stage company focused on revolutionizing the measurement of intracranial pressure (ICP) with their innovative IPASS technology. This non-invasive solution aims to provide rapid and safe ICP assessments, addressing the critical need for better management of traumatic brain injury (TBI) and other conditions associated with elevated cranial pressure. By eliminating the need for invasive procedures, CranioSense is poised to significantly improve patient outcomes and healthcare practices.

Frontier Bio creates lab-grown human tissues to eliminate the organ transplant list and as an ethical alternative to animal studies. They're starting with blood vessels since they are the foundation for all tissues.

GreenLifeTech is dedicated to improving sustainability by extending the shelf life of fresh produce, thereby reducing food waste and promoting healthier living. In addition, the technology is applicable to preserving transfusion blood. Their initial innovative product, FreshDefend™, is a smart countertop system that can extend the life of fruits and vegetables by up to five times without the use of harmful chemicals. The company is committed to environmental sustainability, reducing agricultural waste, and supporting communities through charitable donations.

Gryphon Bio is a clinical stage company focused on developing novel blood tests for brain health, leveraging over 20 years of -omic research to identify brain-specific biomarkers in the blood. Their mission is to improve patient lives through innovative diagnostics for various central nervous system (CNS) diseases.

KaloCyte, Inc. is a pre-clinical stage biotech company focused on developing ErythroMer™, a dried, bio-inspired artificial red blood cell that is shelf-stable without refrigeration. This innovative solution aims to address the critical need for blood substitutes in emergency situations where stored red blood cells are unavailable, undesirable, or in short supply. Founded by a team of experts in physiology, bioengineering, and trauma care, KaloCyte is supported by significant federal grants and investor funding, positioning it to advance to first-in-human trials.

Lumen Bioscience is dedicated to unlocking the full potential of biologic drugs by transforming their development, cost, and accessibility. Utilizing patented technology, Lumen aims to develop biologic drugs faster, safer, and more effectively than traditional methods, addressing diseases that have been neglected by conventional drug-making tools.

Matregenix is a global leader in nanofiber technology, specializing in highly customizable nanofibrous materials for diverse applications, particularly in filtration and biomedical fields. The company is committed to pushing the boundaries of nanofiber technology through innovative platforms and state-of-the-art electrospinning machines, providing comprehensive contract development and manufacturing services to help manufacturers bring their innovations to market.

MyndBlue: Redefining Mental Health Care with Bold Innovation Step into the future of mental readiness with MyndBlue, a visionary MedTech pioneer revolutionizing how mental health is diagnosed and treated. We blend groundbreaking physiological insights with the brilliance of advanced AI to deliver precision-driven, personalized clinical solutions that set a new standard in care. At MyndBlue, we’re on a mission to transform lives of by equipping physicians with dynamic, real-time tools to identify and predict conditions like Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). Our cutting-edge technology empowers earlier, smarter interventions—unlocking better outcomes and illuminating a hopeful path forward for mental health.

NeuEsse Inc. is dedicated to advancing skin health through innovative plant-based technologies. Their mission is to provide effective solutions for skin repair, addressing challenges such as severe burns, wounds, and trauma. Their flagship product, OmegaSkin™, is a human skin substitute made from soy protein, designed to enhance healing outcomes with minimal scarring. NeuEsse aims to meet the unmet needs in wound treatment, offering products that are sustainable, vegan-friendly, and require no special handling.

Nostopharma is a preclinical stage pharmaceutical innovator developing treatments to address unmet needs in musculo-skeletal health. According to the World Health Organization (WHO), approximately 1.71 billion people worldwide have musculoskeletal conditions. Nostopharma is developing a proprietary sustained delivery nanoformulation platform that was validated with the first therapeutic product that addresses the critical issue of trauma-induced abnormal bone growth. Other complications from trauma often include post-surgical infections, severe bleeding, acute localized inflammation, chronic pain management, and other challenges. Nostopharma envisions developing a precision medicine, "on-demand" platform to facilitate flexible combination treatments in surgical settings, aiming to achieve "complication-free" recovery for millions of trauma patients. While trauma patients are treated by orthopedic surgeons for bone repair as standard care, their accompanying soft tissue trauma goes unattended. In part, this is due to the lack of medical treatments available to trauma teams and orthopedic surgeons for use in pre-hospital settings and during surgery. Nostopharma’s treatments will be administered as rapid-response measure, pre- and post-operatively, and significantly improve the outcomes for trauma patients by facilitating the complication-free recovery. For the first time, orthopedic surgery and trauma patients will be able to take potent and proven medications without exposure to their toxicities as systemic drugs. Nostopharma has assembled a world-class team and advisory board, complemented by the best-in-class contract toxicology and manufacturing organizations to de-risk product development execution. Additionally, Nostopharma’s technology offers a versatile and advanced platform for the delivery of other therapeutics, addressing unmet needs of military and civilian trauma (e.g., infections and poor pain management). Nostopharma is following a very capital-efficient pathway (505(b)2 regulatory framework) to enter in the clinic as early as 2026 direct to Phase 2 trial. Discussions with several strategic partners like Johnson&Johnson (DePuy), UBS Pharma, Pfizer, and Stryker have confirmed the potential to partner and license NP102-nano and future pipeline products for commercialization after the successful Phase 2 clinical trial.

Owl Therapeutics is dedicated to developing neurotherapeutics aimed at enhancing the function of microglia, which are crucial for clearing brain cell debris and inflammation resulting from brain injuries and diseases. The company focuses on providing hope for patients suffering from traumatic brain injury (TBI), Alzheimer's disease (AD), and related conditions.

Pneuma Systems Corporation specializes in designing and licensing closed-loop fluid control systems that precisely manage small fluid volumes without the complexity of traditional pumping mechanisms. The company leverages over 30 inventions and three novel subsystems to revolutionize fluid flow, workflow, information flow, and cash flow, aiming to transform the standard of care in infusion therapy. Pneuma is a small team of experienced medical device professionals working on a new technology platform for precise fluid delivery, with an emphasis on infusion therapy. Armed with a strong IP portfolio, Pneuma’s infusion controller is designed to support all venues of infusion therapy including acute care, standalone infusion centers, and home care. The design offers significant advances in fluid flow, information flow, and work flow. The design has been accepted into an accelerated review program by the U.S. Food and Drug Administration (FDA), known as STeP.

PyrAmes is a digital health company focused on transforming healthcare delivery through advanced sensor measurement. The company is developing a proprietary platform for continuous, accurate, wireless, and non-invasive blood pressure monitoring for patients of all ages, from newborns to seniors. PyrAmes aims to make blood pressure monitoring easy, low-cost, unobtrusive, and painless, ultimately improving patient outcomes.

RelīOx Corporation specializes in innovative chlorine dioxide technology, providing a safe, on-demand production method that eliminates the need for dangerous chemicals. Developed from research at the University of Florida, their patented technology offers environmentally friendly solutions for various industrial and commercial applications.

Sempulse is a pioneering company that empowers medical professionals with advanced non-invasive monitoring technology. Their flagship product, the Halo Vital Signs Monitor, allows for real-time tracking of multiple patients' vital signs from a single device, enhancing patient care and operational efficiency in various healthcare settings. Sempulse's mission is to improve patient outcomes through innovative technology that integrates seamlessly into existing healthcare systems.

Sense Neuro Diagnostics is dedicated to developing non-invasive technology for the rapid detection and monitoring of stroke and traumatic brain injuries (TBI). Their mission is to improve patient outcomes by providing real-time assessments that enhance the efficiency of care in emergency situations.